Editas Medicine, Inc. — Q1 2023 Form 10-Q
Business context and reporting period. Clinical-stage genome-editing company; unaudited results cover the three months ended March 31, 2023, compared with Q1 2022. Editas has no product sales and relies on collaboration income and financing.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Collaboration and other R&D revenue | $9.9 million | $6.8 million |
| Research and development expense | $37.8 million | $38.0 million |
| General and administrative expense | $23.0 million | $19.5 million |
| Operating loss | $51.0 million | $50.8 million |
| Net loss | $49.0 million; $0.71 per share | $50.5 million; $0.74 per share |
| Operating cash used | $35.8 million | $49.2 million |
| Cash, cash equivalents and marketable securities | $401.8 million at March 31, 2023 | $437.4 million at December 31, 2022 |
Revenue increased 45%, primarily reflecting the January 2023 sale of oncology assets and related licenses. Operating expenses rose 6%; lower R&D spending was offset by higher G&A. Higher interest income helped reduce net loss year over year. Gross margin is not applicable as presented; the filing reports no product revenue.
Cash, cash equivalents and restricted cash declined $12.5 million during the quarter. Total liabilities were $146.6 million, including $37.1 million of operating lease liabilities and $68.9 million of deferred revenue. The filing reports no debt balance. The company expects its March 31 cash and investments to fund operations and capital expenditures into 2025, but says it will need substantial additional capital. It had an unused ATM facility permitting up to $300 million in gross stock sales.
Programs, changes and outlook
- EDIT-301: RUBY SCD trial had 19 patients enrolled; the company remained on track to dose 20 patients by year-end 2023 and expected updates in June and by year-end. The first EDITHAL TDT patient was dosed in Q1 and achieved neutrophil and platelet engraftment; data were expected by year-end. FDA granted EDIT-301 Orphan Drug Designation in April 2023, after the quarter.
- EDIT-101: Enrollment in the inherited retinal disease program remained paused. The company said the responder population identified from trial data was too small to progress the program independently.
- In January 2023, Editas sold EDIT-202 and another iNK program, related manufacturing technology, and specified technology rights to Shoreline Biosciences. The transaction drove the Q1 revenue increase.
- Management expects significant expenses and operating losses to continue and does not expect profitability in 2023 or the foreseeable future. R&D costs are expected to increase as clinical and preclinical programs advance.
Risks, contingencies and unusual items
- Clinical, regulatory, manufacturing and commercialization outcomes are uncertain; programs may fail or require more time and capital than forecast. Cash-runway estimates depend on assumptions and actual needs could arise sooner.
- Editas incurred $3.0 million in Q1 expense reimbursing Broad and Harvard for patent-related costs. The company anticipates a substantial commitment related to patent interference and opposition proceedings, but the amount is not determinable.
- Future milestone and royalty obligations under licenses are contingent on development, regulatory and commercial events. Non-cancelable operating lease payments totaled $46.1 million, including $8.2 million payable in 2023.
- Investments expose the company primarily to interest-rate risk; management said an immediate 100-basis-point rate change would not materially affect fair value. The filing reported no material foreign-exchange exposure.
Important facts for investors to verify
- Whether the RUBY and EDITHAL dosing and data-update targets were met, and how subsequent clinical evidence affects safety, efficacy and development plans.
- Whether cash use and collaboration or licensing receipts support the stated runway into 2025, and whether additional financing or dilution becomes necessary.
- The financial terms and any continuing obligations associated with the Shoreline transaction, including the timing and collectability of related revenue.
- Developments and potential costs in Broad/Harvard patent proceedings and other intellectual-property disputes.
- Future collaboration milestones, revenue recognition and the use of the unused ATM facility.